The FDA closed the WHOOP blood-pressure letter. The two words that matter are 'as modified.'

Eleven months after it told WHOOP that an estimated-blood-pressure feature was on the wrong side of the line between wellness and medicine, the FDA has closed the matter. The close-out letter, dated June 17 and posted this week, says that based on changes the company made to the feature and its labeling, the agency does not intend to enforce device requirements for the product "as modified," and that the determination applies to that product only. It cites the agency's general-wellness guidance, updated in January. The company's chief executive called the outcome positive for consumers and for wellness innovation. The trade press called it the FDA backing down. We would call it something narrower, and the narrow version is the one that matters to anyone with a band on their wrist.

What was and wasn't decided. The letter does not say the feature is accurate, cleared or approved; it says the agency will not pursue a modified version, and it does not describe the modifications. In July the objection was to a medical-grade framing, daily systolic and diastolic estimates and a color-coded gauge. Something about that has changed, and the company has not said what. Read with the Apple clearance in September — a screening flag that sends you to a cuff, cleared on published performance data — the two outcomes draw the line the industry now lives on: you may show a wellness number about blood pressure if you stop implying it is a measurement, and you may make a medical claim if you clear it. The company chose the first door. The reader should know which door they walked through.

Ben’s take

Call it what it is: a settlement in which the product was changed and nobody said how. That is a fine outcome for the company, which raised $575 million at a $10.1 billion valuation in April with this question open, and a reasonable one for the agency, which got its modification without a fight. It is a worse outcome for the customer, who now sees a blood-pressure feature that the regulator has declined to object to and will read that as a blessing. "Does not intend to enforce" is not an endorsement. It is an exhaustion.

Loree’s take

Nothing about today changes what I tell patients: the band cannot measure your blood pressure, and whatever it now shows you about it has not been shown to match a cuff. If the feature nudges you to buy a cuff and use it, good. If it replaces the cuff, the modification did not go far enough. A regulator's decision not to act is not a clinical fact. The cuff is.

Why it matters to a recovering optimizer. The wearable industry's most valuable asset is the wellness carve-out, and this letter shows how it is defended: not by proving a feature works, but by rewording it until it no longer claims to. That is lawful and it is not evidence. For anything on your wrist that touches a diagnosis, the standard is unchanged — a cleared device or a validated instrument — and the FDA did not say otherwise this week. It said it would not pursue the matter. Those are different sentences.